-+ 0.00%
-+ 0.00%
-+ 0.00%

Innate Pharma Regains SAR'579 Rights For AML As Sanofi Proposes €15M Strategic Equity Investment

Benzinga·04/23/2025 05:45:35
Listen to the news
  • Innate to regain its rights on CD123 targeting ANKET® SAR443579 (SAR'579) /IPH6101 currently in development for AML
  • Potential investment of up to €15M by Sanofi in Innate Pharma through a capital increase, subject to market conditions
  • Sanofi to continue development of BCMA targeting ANKET® program in autoimmune indications
  • Innate still eligible for more than €1 billion R&D and commercial milestones